Alpha-fetoprotein is a traditional cancer biomarker that is used to monitor HCC treatment and recurrence; however, 35–45% of HCC patients have low serum AFP levels (<20 μg/L) (Sherman et al., 1995; Cedrone et al., 2000; Trevisani et al., 2001). This evidence concerns the gene AFP and cancer.